Topics covered: The slowdown in approvals, The pharma model, The pace of external deals, The key franchises, The generic risk, The development cost, The business model, Management Teams, Drug development, Branded specialty pharmaceuticals, Aggressive generic challenges, A series of pipeline disappointments